PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Tolcapone - Parkinson's disease
PAD Profile : Tolcapone - Parkinson's disease
Keywords :
PD
Brand Names Include :
Tasmar
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Apomorphine hydrochloride
- Safinamide
- Opicapone
- Co-beneldopa (Benserazide/levodopa)
- Co-careldopa (Carbidopa/levodopa)
- Pramipexole
- Ropinirole hydrochloride
- Bromocriptine
- Pergolide mesilate
- Cabergoline
- Rasagiline mesilate
- Selegiline hydrochloride
- Entacapone
- Amantadine hydrochloride
- Orphenadrine hydrochloride
- Procyclidine hydrochloride
- Trihexyphenidyl hydrochloride
- Clonazepam
- Melatonin
- Rotigotine
- Levodopa/carbidopa/entacapone
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Shared Care
31 March 2020
Shared Care
31 March 2020
Committee Recommendations
Date
Committee Name
Narrative
28 August 2013
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
It was noted that this drug is now rarely used but it was agreed that it would be useful to have a shared care document agreed for the occasional patient in whom it would be appropriate to use. The PCN supported the shared care document.
Associated BNF Codes
04. Central Nervous System
04.09.01. Dopaminergic drugs used in parkinsonism